Sign in
Taking people in South KoreaPhase 2

Testing asciminib to help chronic myeloid leukemia patients stay off treatment

Tests asciminib with other drugs in adults with chronic myeloid leukemia.

Key facts

Who runs it
Korean Society of Hematology
Where
Incheon, South KoreaSee the site
Trial code
Registry title
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
Status
Recruiting
Phase
Phase 2
People taking part
69 people, planned
Started
11 Mar 2024
Expected to end
31 Aug 2028
Type of study
Interventional
Treatments tested
  • Asciminib
Record updated
2 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic phase chronic myeloid leukemia whose disease came back after they stopped their TKI medicine, and who are back in deep remission on TKI again.

Age
19 years or older
Sex
All sexes can join
Disease stage
Chronic phase chronic myeloid leukemia (CP-CML)
Earlier treatment
Taking imatinib, nilotinib or dasatinib for 5 years or more. Failed to keep MR3.0 after 1 or more TKI stop attempts. Back on TKI for over 12 weeks and has regained MR3.0 or a deeper response. Must agree to stop asciminib and TKIs after keeping MR4.5 for the required time.
Biomarker or test result
Molecular response MR3.0 or deeper at screening

Main reasons for not taking part

  • Grade 3 or higher side effects from imatinib, dasatinib or nilotinib
  • Earlier CAR-T cell therapy, allogeneic stem cell transplant or biologic therapy
  • Uncontrolled infection, or active hepatitis B or C that is not controlled
  • Another cancer that needs treatment
  • Pregnant women

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • 19 year or older
  • CP-CML patients who are taking current TKIs (imatinib, nilotinib or dasatinib) for 5 years or more
  • Patients who have failed maintaining MR3.0 after 1 or more cessation trial of TKIs
  • Patients who regained MR3.0 or deeper molecular response by TKIs retrial after TKI cessation failure at the time of screening
  • Taking TKIs over 12 weeks for the retrial of TKIs after TKI cessation failure
  • Patients who agree with stopping asciminib and TKIs after maintaining 23 year-duration of MR4.5
  • Adequate end organ function as defined by:; Total bilirubin (TBL) < 3 x upper limit of normal (ULN); patients with Gilbert's syndrome may only be included if TBL ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN; Creatinine clearance (ClCr) ≥ 30 mL/min as calculated using Cockcroft-Gault formula; Serum lipase ≤ 1.5 x ULN. For serum lipase > ULN - ≤ 1.5 x ULN, value must be considered not clinically significant and not associated with risk factors for acute pancreatitis
  • Patients who can sign the informed consent of their own free will

Who cannot take part

  • Patients who are receiving any other investigational agents
  • Patients who previously received Chimeric antigen receptor T-cell (CAR-T cell) therapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) or biologic therapy
  • Patients who have a history of thromboembolic episodes within 3 months prior to the study enrollment
  • Pregnant women are excluded from this study Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with asciminib and TKIs, breastfeeding should be discontinued if the mother is treated with asciminib and TKIs
  • Patients who currently have uncontrolled infections
  • Patients with clinically significant cardiovascular disease or gastrointestinal dysfunction
  • Patients with active hepatitis B or C with uncontrolled disease activity
  • Patients who have active malignancies requiring treatment other than CML
  • Patients with any severe and/or uncontrolled medical conditions or other conditions that could adversely impact on patients' ability to participate in the study
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements
  • Patients who experienced grade 3 or higher adverse events with TKIs (imatinib, dasatinib, and nilotinib)

Where in South Korea

  • Gachon University Gil Medical CenterIncheon, South KoreaContact: Eunju ParkTaking people

About the trial

What the trial wants to find out

To evaluate the efficacy of asciminib adding on tyrosine-kinase inhibitors (TKI) to achieve treatment-free remission (TFR) in chronic myeloid leukemia (CML) patients in chronic phase who failed prior cessation study of TKI

The group in the trial

  • Asciminib armOther group

    Treatment: Asciminib

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia in Combination With Asciminib and Tyrosine Kinase Inhibitors
Plain-language title
Testing asciminib to help chronic myeloid leukemia patients stay off treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 April 2026